¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ ]f1 {n  
J "FC%\|  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© IVW1]y  
5K?}}Frrt`  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© #h@J=Ki  
\Y}3cE  
1.Co-stimulators (or co-stimulating molecules) 3 LdQ]S  
fJWC)E  
2.NK-kB CX m+)a-L  
Y\0}R,]a-  
3.Immunoglobulin superfamily z  ;u  
/>j';6vi  
4.antigen-presenting cell (APC) !*`-iQo&  
] 7 _`]7p  
5.death domain !'Q -yoHKD  
WF\)fc#;_o  
6.CCR and CXCR KeNL0_ Pw  
^3hn0DVQ  
7.Lectin (or mitogen) HD N9.5 S  
6K-5g/hL  
8.Clusters of differentiation, CD) nbG/c80  
. <tq6 1  
9.B7 family hkO sm6  
2On_'^O  
10.Cytotoxic T lymphocyte, CTL) P4Th_B7  
G7=p Bf  
11.IL-15 and IL-15 receptor (IL-15R) 9!><<7TS  
# 6! 5 2  
12.MHC restriction j:w{;(1=W  
3~#h|?  
13.Affinity-chromatography a {ab*tM  
,j5&6X=1M  
14.Cyctosprin A, CsA w}{5#   
XW?b\!@ $  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) "6a8s;  
vLxQ *50v$  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© Ys!>+nL|  
kPjd_8z2n  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 zX#%{#9  
bZx!0> h  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ +I>p !v  
`nO71mo  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ JH7Ad (:  
KgW:@X7wvM  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© p N\Vr8tJ  
3Oa*%kP+  
ÃâÒßѧרҵ£º "G:<7oTa  
7E!7"2e a  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ *MI*Rz?4  
3 DaQo 0N  
Ïû»¯ÄÚ¿Æ£º "S&%w8V  
VGqa)ri"  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ _p?s9&  
5( _6+'0  
ѪҺ²¡Ñ§×¨Òµ£º A>VX*xd  
h3gWOU  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
freekaobo¹Ù·½Î¢ÐŶ©ÔĺŠÕýÈ·´ð°¸:¿¼²©
°´"Ctrl+Enter"Ö±½ÓÌá½»